Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease

A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound of formula (I):

• wherein:
• R1 is selected from the group consisting of H and halo,
• wherein R1 is ortho to the
• substituent;
• R2 is selected from the group consisting of H and halo,
• wherein R2 is para to the
• substituent;
• with the proviso that R1 and R2 are not simultaneously H;
• R3 is selected from the group consisting of H, cyano, halo, nitro, C1-6 alkyl, heteroalkyl, carboxy, alkylcarboxy, formyl, and alkyl-carbonyl;
• R4 is selected from the group consisting of H and C1-3 alkyl;
• R5 is selected from the group consisting of H, C1-3 alkyl, substituted C1-3 alkyl, and heteroalkyl;
• and,
• n is 2;
• or a pharmaceutically acceptable salt thereof.